Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
テクノロジー·イーライ・リリー

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
テクノロジー·イーライ・リリー

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% 確率
Polymarket

$11,264 Vol.

13% 確率
Polymarket

$11,264 Vol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly's existing 2024 research collaboration with Peptron grants only a non-exclusive license for internal evaluation of SmartDepot's sustained-release microsphere technology on peptide drugs, with no confirmed path to a commercial deal. Traders see the 87.5% probability of no full licensing by the early-October 2026 deadline as driven by Lilly's strategic pivot toward oral obesity candidates, ongoing uncertainty around technology evaluation timelines, and the absence of recent regulatory filings, partnership announcements, or supply-chain signals. The short window leaves little room for the multi-month negotiations, IP reviews, and milestone validations typical in pharma licensing, reinforcing market consensus around the status quo.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
音量
$11,264
終了日
2026/10/07
マーケット開始日
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly's existing 2024 research collaboration with Peptron grants only a non-exclusive license for internal evaluation of SmartDepot's sustained-release microsphere technology on peptide drugs, with no confirmed path to a commercial deal. Traders see the 87.5% probability of no full licensing by the early-October 2026 deadline as driven by Lilly's strategic pivot toward oral obesity candidates, ongoing uncertainty around technology evaluation timelines, and the absence of recent regulatory filings, partnership announcements, or supply-chain signals. The short window leaves little room for the multi-month negotiations, IP reviews, and milestone validations typical in pharma licensing, reinforcing market consensus around the status quo.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
音量
$11,264
終了日
2026/10/07
マーケット開始日
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

関連

icon for FDAは今年レタルチュルタイドを承認しますか？

FDAは今年レタルチュルタイドを承認しますか？

3%
はい
icon for 2026年8月14日のChatGPTの障害？

2026年8月14日のChatGPTの障害？

35%
はい
icon for 2026年8月31日までにChatGPTが停止するか？

2026年8月31日までにChatGPTが停止するか？

82%
はい

外部リンクに注意してください。

よくある質問

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」はPolymarket上の予測市場で、トレーダーがこのイベントが起こるかどうかに基づいて「はい」または「いいえ」のシェアを売買します。コミュニティによる現在の確率は「Yes」に対して13%です。例えば、「はい」が13¢で取引されている場合、市場はこのイベントが発生する確率を13%と集合的に評価しています。これらのオッズはトレーダーが新しい展開や情報に反応するにつれて継続的に変化します。正しい結果のシェアは市場決済時に各$1で引き換え可能です。

本日現在、「Eli Lilly licenses Peptron’s SmartDepot by October 7?」は$11.3Kの総取引量を生み出しています（May 5, 2026のマーケット開始以来）。この取引活動レベルはPolymarketコミュニティの強い関与を反映し、現在のオッズが幅広い市場参加者によって形成されていることを保証します。このページで直接、ライブの価格変動を追跡し、任意の結果で取引できます。

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」で取引するには、答えが「はい」か「いいえ」かを選ぶだけです。各側には市場の暗示確率を反映する現在の価格があります。金額を入力して「取引」をクリックします。「はい」のシェアを購入し、結果が「はい」と決まった場合、各シェアは$1を支払います。「いいえ」と決まった場合、「はい」のシェアは$0を支払います。決済前にいつでもシェアを売却して利益を確定したり、損失を抑えたりすることもできます。

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」の現在の確率は「Yes」に対して13%です。これはPolymarketコミュニティがこのイベントの発生確率を13%と現在評価していることを意味します。これらのオッズは実際の取引に基づいてリアルタイムで更新され、市場の期待を継続的に反映するシグナルを提供します。

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」の決済ルールは、各結果が勝者と宣言されるために何が起こる必要があるかを正確に定義しています。これには結果を決定するために使用される公式データソースも含まれます。このページのコメント上にある「ルール」セクションで完全な決済基準を確認できます。取引前にルールを注意深く読むことをお勧めします。